These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
380 related items for PubMed ID: 20064514
1. Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. Sandborn WJ, Korzenik J, Lashner B, Leighton JA, Mahadevan U, Marion JF, Safdi M, Sninsky CA, Patel RM, Friedenberg KA, Dunnmon P, Ramsey D, Kane S. Gastroenterology; 2010 Apr; 138(4):1286-96, 1296.e1-3. PubMed ID: 20064514 [Abstract] [Full Text] [Related]
2. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Dignass AU, Bokemeyer B, Adamek H, Mross M, Vinter-Jensen L, Börner N, Silvennoinen J, Tan G, Pool MO, Stijnen T, Dietel P, Klugmann T, Vermeire S, Bhatt A, Veerman H. Clin Gastroenterol Hepatol; 2009 Jul; 7(7):762-9. PubMed ID: 19375519 [Abstract] [Full Text] [Related]
3. Once-daily MMX(®) mesalamine for endoscopic maintenance of remission of ulcerative colitis. D'Haens G, Sandborn WJ, Barrett K, Hodgson I, Streck P. Am J Gastroenterol; 2012 Jul; 107(7):1064-77. PubMed ID: 22565161 [Abstract] [Full Text] [Related]
4. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. Sandborn WJ, Regula J, Feagan BG, Belousova E, Jojic N, Lukas M, Yacyshyn B, Krzeski P, Yeh CH, Messer CA, Hanauer SB. Gastroenterology; 2009 Dec; 137(6):1934-43.e1-3. PubMed ID: 19766640 [Abstract] [Full Text] [Related]
5. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Hanauer SB, Sandborn WJ, Kornbluth A, Katz S, Safdi M, Woogen S, Regalli G, Yeh C, Smith-Hall N, Ajayi F. Am J Gastroenterol; 2005 Nov; 100(11):2478-85. PubMed ID: 16279903 [Abstract] [Full Text] [Related]
11. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Feagan BG, Macdonald JK. Cochrane Database Syst Rev; 2012 Oct 17; 10():CD000543. PubMed ID: 23076889 [Abstract] [Full Text] [Related]
12. A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis. Kane S, Huo D, Magnanti K. Clin Gastroenterol Hepatol; 2003 May 17; 1(3):170-3. PubMed ID: 15017487 [Abstract] [Full Text] [Related]
13. Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis. Flourié B, Hagège H, Tucat G, Maetz D, Hébuterne X, Kuyvenhoven JP, Tan TG, Pierik MJ, Masclee AA, Dewit O, Probert CS, Aoucheta D, MOTUS study investigators. Aliment Pharmacol Ther; 2013 Apr 17; 37(8):767-75. PubMed ID: 23451806 [Abstract] [Full Text] [Related]
17. Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study. D'Haens G, Hommes D, Engels L, Baert F, van der Waaij L, Connor P, Ramage J, Dewit O, Palmen M, Stephenson D, Joseph R. Aliment Pharmacol Ther; 2006 Oct 01; 24(7):1087-97. PubMed ID: 16984503 [Abstract] [Full Text] [Related]